SureTrader SureTrader
Home > Boards > US OTC > Medical - Healthcare >

InVivo Therapeutics Holdings Corp (NVIV)

Add NVIV Price Alert      Hide Sticky   Hide Intro
Moderator: TheHound
Search This Board:
Last Post: 11/28/2016 8:13:36 PM - Followers: 197 - Board type: Free - Posts Today: 0

About InVivo Therapeutics 

InVivo Therapeutics Corporation is a Cambridge, MA based medical device company founded to develop and commercialize groundbreaking technologies for the treatment of spinal cord injuries (SCI).Currently, there are no treatment options for SCI patients to successfully restore function following a spinal cord injury. Existing treatments consist of a collection of approaches that only focus on symptoms of SCI, such as decompression and mechanical stabilization of the spinal cord, rather than on the underlying pathology. InVivo intends to develop its novel Neuro-Spinal Scaffold to treat acute SCI and Neuro-Scaffold Plus Stem Cells to treat chronic SCI. - See more at:

In the Spotlight

October 23, 2015 InVivo Therapeutics Reports Significant Improvement of First Patient Implanted with Neuro-Spinal Scaffold™

October 19, 2015   InVivo Therapeutics Announces Expansion of Number of Patients in Pilot Study

October 1, 2015 Early Promise for a New Paralysis Treatment

September 9, 2015 InVivo Therapeutics Announces Mount Sinai Hospital in New York City as New Site for Neuro-Spinal Scaffold™ Clinical Trial

September 8, 2015 InVivo Therapeutics Announces Enrollment of Fifth Patient in Pilot Spinal Cord Injury Study

August 20, 2015 InVivo Therapeutics Announces Enrollment of Fourth Patient in Pilot Spinal Cord Injury Trial

August 13, 2015 InVivo Therapeutics’ CEO and Chairman, Mark Perrin, Interviewed by Maria Bartiromo on FOX Business Network’s “Mornings with Maria”

July 6, 2015 InVivo Therapeutics Reports Significant Improvement of Second and Third Patients Implanted with Neuro-Spinal Scaffold

June 22, 2015 InVivo Therapeutics Receives Notice of Allowance on Patent Covering Broader Compositions for Neuro-Spinal Scaffold and Neuro-Spinal Scaffold Plus Stem Cells

June 5, 2015- InVivo Therapeutics Announces Enrollment of Third Patient in Pilot Spinal Cord Injury Trial

April 16, 2015InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) to Ring The Nasdaq Stock Market Opening Bell

April 8, 2015 - InVivo Therapeutics Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to NASDAQ

March 26, 2015 - InVivo Therapeutics Announces Reopening of Enrollment for Subjects Three through Five for Anticipated Completion of Ongoing Pilot Trial

March 11, 2015 - InVivo Therapeutics Reports 2014 Year End Financial Results and Business Update

February 23, 2015 - InVivo Therapeutics Announces Froedtert & the Medical College of Wisconsin as New Clinical Trial Site for Neuro-Spinal Scaffold

February 9, 2015 - InVivo Therapeutics Appoints Lorianne Masuoka, MD as Chief Medical Officer

February 5, 2015 - InVivo Therapeutics Announces CEO Mark Perrin Named Chairman of the Board

February 2, 2015 - Video - Second Implantation of InVivo Therapeutics Neuro-Spinal Scaffold In Charlotte

January 22, 2015 - InVivo Therapeutics Announces Enrollment of Second Subject in Pilot Spinal Cord Injury Trial

January 21, 2015 - Zacks Small Cap Research Report- $3.25 Price Target

January 21, 2015 - Jordan's 1st Patient Video

January 21, 2015 - InVivo Therapeutics Reports Three-Month Update of First Acute Spinal Cord Injury Subject Implanted with Neuro-Spinal Scaffold

December 18, 2014 - Microcap - NVIV Research Report **A MUST READ**

December 16, 2014 - InVivo Therapeutics Announces FDA Approval to Expedite Enrollment for Ongoing Pilot Trial

November 11, 2014 - Scottsdale man hopes to walk again after groundbreaking surgery

October 29, 2014 - InVivo Therapeutics Receives FDA Approval to Broaden Inclusion Criteria and Add 14 Additional Sites (20 Total) for Ongoing Pilot Trial

October 15, 2014 - InVivo Therapeutics Announces First Subject Enrolled in Pilot Spinal Cord Injury Trial

April 28, 2014 - InVivo Therapeutics Initiates First Clinical Trial of Neuro-Spinal Scaffold


Ongoing Human Trials:
SEC Filings:
Recent News:
Share Structure:
Investor Presentation:



All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
NVIV News: InVivo Therapeutics Announces New Patient Enrollment into The INSPIRE Study 11/17/2016 08:00:00 AM
NVIV News: InVivo Therapeutics to Present at Neuroscience 2016 11/10/2016 08:00:00 AM
NVIV News: InVivo Therapeutics Announces University of Iowa Hospitals and Clinics as New Site for INSPIRE Study 11/09/2016 08:00:00 AM
NVIV News: InVivo Therapeutics Reports 2016 Third Quarter Financial Results and Business Update 11/04/2016 04:30:00 PM
NVIV News: Quarterly Report (10-q) 11/04/2016 04:10:45 PM
#5292  Sticky Note A Year in Review: 2015 FactMan777 01/03/16 12:24:23 AM
#5656   gotcha. that makes sense. i think it's been TheHound 11/28/16 08:13:36 PM
#5655   Hound, you just agreed with me last week. BioBull1 11/28/16 07:56:52 PM
#5654   i see no mention of 21 patients in TheHound 11/28/16 03:25:14 PM
#5653   correct. Potentially up to 21 patients per the BioBull1 11/28/16 02:46:25 PM
#5652   9 viable patients in over 2 years? is blackbandit 11/25/16 10:52:17 PM
#5651   That would be incorrect... BioBull1 11/23/16 11:18:13 AM
#5650   9 more patients needed to complete the study. MDizzle 11/22/16 03:40:27 PM
#5649   Agree. In regard to 30 patients, this was what TheHound 11/18/16 11:31:55 AM
#5648   Hound, the clinical trial site has stated June BioBull1 11/18/16 09:16:37 AM
#5647   Anyone know what this device is? uksausage 11/18/16 08:48:33 AM
#5646   u didn't even get the question right. here TheHound 11/18/16 12:19:37 AM
#5645   You asked me what kind of person uses DDobserver 11/17/16 11:08:28 PM
#5644   up-2-date clinical trial info: TheHound 11/17/16 05:17:52 PM
#5643   Have you heard: why the slow down in Devo33 11/17/16 04:35:32 PM
#5642   Who in their right mind looks for intrinsic TheHound 11/17/16 03:40:15 PM
#5641   Perrin has been saying that all year regarding pace. BioBull1 11/17/16 02:40:33 PM
#5639   the SP that was required for NVIV to TheHound 11/17/16 01:23:21 PM
#5638   If I am wrong prove your position show DDobserver 11/17/16 01:18:09 PM
#5637   wrong again. TheHound 11/17/16 12:32:55 PM
#5636   wrong. the minimum bid price requirement stems from TheHound 11/17/16 12:06:40 PM
#5635   "we expect enrollment to increase in the coming Devo33 11/17/16 11:40:55 AM
#5633   InVivo Therapeutics Announces New Patient Enrollment into The MDizzle 11/17/16 08:18:08 AM
#5632   make u smart and disprove ur thoughts? lol. TheHound 11/17/16 12:06:26 AM
#5631   Yes it is up. What happened is market DDobserver 11/16/16 11:12:05 PM
#5630   here's a fact. up over 35% since we TheHound 11/16/16 05:43:01 PM
#5629   Thank you for the response. I read your DDobserver 11/15/16 09:46:25 PM
#5628   I will try, just for the sake of Devo33 11/15/16 11:06:29 AM
#5627   Thanks for the reply and I do not DDobserver 11/13/16 02:15:31 PM
#5626   Look Pal I am not here to argue joepcf 11/13/16 11:38:37 AM
#5625   I have spent hundreds of hours over the DDobserver 11/13/16 04:53:47 AM
#5624   Dr Langer teamed up with our ex CEO joepcf 11/13/16 12:34:36 AM
#5623   The 20% I attribute to emotion and a DDobserver 11/12/16 11:44:04 AM
#5622   up over 20% in a few weeks. nice dshade 11/12/16 11:00:17 AM
#5621   No they do not. This is overpriced by DDobserver 11/12/16 12:47:36 AM
#5620   buys of the 4s are looking nice. dshade 11/11/16 04:01:15 PM
#5619   I believe replacement of Obama Care would be DDobserver 11/10/16 10:30:32 PM
#5618   What do you think of the "Repeal and Devo33 11/10/16 01:15:50 PM
#5617   I can respect your opinion but as far DDobserver 11/09/16 03:51:59 PM
#5616   Based on the only metric that matters right Lazed 11/09/16 01:10:48 PM
#5615   27 respected, professional, exceptional medical institutions have thrown Devo33 11/09/16 11:56:19 AM
#5614   From your response it appears you also read DDobserver 11/09/16 09:58:57 AM
#5613   Yay. Another site that will never perform the Lazed 11/09/16 08:52:04 AM
#5612   InVivo Therapeutics Announces University of Iowa Hospitals and MDizzle 11/09/16 08:12:03 AM
#5611   Interesting post. I am glad that you recognized, DDobserver 11/07/16 09:45:44 PM
#5610   Yea it seems like he has a good Petiedawgs 11/07/16 05:03:00 PM
#5609   Going long bought in about a week or Petiedawgs 11/07/16 04:58:20 PM
#5608   What a welcomed addition! TheHound 11/03/16 10:33:21 AM
#5607   Another addition to the BOD. Let's simply add BioBull1 11/02/16 09:17:33 AM
#5606   Was the dollar per share you made worth DDobserver 11/01/16 11:01:57 PM
#5605   made $1 per share on bounce. that is dshade 11/01/16 02:31:38 PM